Skip to main content
    C

    Climb Bio Inc (CLYM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.94
    -0.42 (-4.05%)

    Market Cap: $608.53M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Climb Bio Inc (CLYM) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Climb Bio reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$59.85M, operating cash flow was -$54.36M and free cash flow was -$54.54M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$14.57M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $67.88M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Research and development$46.71M$66.00M$15.41M$26.21M$23.32M$18.50M$4.02M
    Operating income-$67.88M-$82.02M-$40.27M-$45.13M-$35.67M-$20.93M-$7.45M
    Net income-$59.85M-$73.90M-$35.12M-$45.24M-$47.48M-$20.67M-$6.55M
    EBITDAN/AN/AN/AN/AN/A-$20.67M-$4.70M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0$0$0-$30.00K$0$0$0N/A$0$0$0N/A
    Operating income-$16.89M-$15.36M-$15.21M-$19.30M-$14.89M-$10.68M-$23.02M-$10.91M-$11.73M-$56.37M-$3.00M-$5.12M
    Net income-$14.57M-$13.50M-$13.72M-$17.52M-$12.89M-$8.67M-$20.78M-$8.42M-$8.89M-$54.89M-$1.70M-$3.64M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $256.00K by $35.43M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$167.74M$217.19M$110.47M$134.99M$173.24M$24.63M$21.39M
    Current assets$105.85M$154.87M$110.25M$134.39M$148.25M$22.00M$21.28M
    Cash and equivalents$35.69M$87.23M$93.11M$43.59M$46.92M$20.49M$21.22M
    Total liabilities$7.27M$5.31M$2.87M$6.28M$6.04M$3.06M$783.00K
    Short-term debt$256.00K$157.00K$334.00K$300.00KN/AN/AN/A
    Shareholder equity$160.47M$211.88M$107.60M$128.72M$167.20M-$24.98M$20.61M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$236.56M$246.29M$152.37M$167.74M$182.30M$192.39M$200.74M$217.19M$222.20M$226.02M$109.33M$110.47M
    Total liabilities$8.51M$6.75M$4.29M$7.27M$5.30M$6.62M$7.36M$5.31M$3.42M$3.74M$2.95M$2.87M
    Cash and equivalents$39.73M$44.11M$8.36M$35.69M$25.80M$22.68M$29.02M$87.23M$146.18M$223.14M$105.03M$93.11M
    Shareholder equity$228.05M$239.55M$148.09M$160.47M$177.00M$185.76M$193.38M$211.88M$218.78M$222.28M$106.38M$107.60M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$54.36M-$15.56M-$20.60M-$37.37M-$36.07M-$14.10M-$5.01M
    Capital expenditures$186.00K$0$0$0$0$0$0
    Free cash flow-$54.54M-$15.56M-$20.60M-$37.37M-$36.07M-$14.10M-$5.01M
    Share repurchases$86.00K$0N/AN/AN/AN/AN/A
    Investing cash flow$2.83M-$121.09M$68.98M$34.44M-$114.97M$8.08MN/A
    Financing cash flow-$21.00K$130.73M$841.00K$0$177.23M$4.92M$26.24M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$12.00M-$10.55M-$14.38M-$15.63M-$12.14M-$11.15M-$15.43M-$5.52M-$7.55M-$667.00K-$1.82M-$947.00K
    Capital expenditures$820.00K$260.00K$0$0$109.00K$77.00K$0$0$0$0$0$0
    Free cash flow-$12.82M-$10.81M-$14.38M-$15.63M-$12.25M-$11.22M-$15.43M-$5.52M-$7.55M-$667.00K-$1.82M-$947.00K
    Last 12 quarters

    Frequently Asked Questions About CLYM

    What is Climb Bio's annual revenue?

    Climb Bio reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Climb Bio profitable?

    No. Climb Bio reported net income of -$59.85M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CLYM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$54.36M minus capital expenditures of $186.00K produced free cash flow of -$54.54M.

    How much debt does Climb Bio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $256.00K and cash and equivalents of $35.69M.